Papillary Thyroid Carcinoma

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy with annual incidence of 14 per 100,000 in the United States and increasing globally, predominantly affecting women (3:1 female-to-male ratio) aged 30-50 years. The increased incidence is partly attributable to detection of small papillary microcarcinomas through neck imaging. PTC is derived from follicular epithelial cells and characterized by characteristic nuclear features (Orphan Annie eye nuclei, nuclear grooves, intranuclear pseudoinclusions, ground-glass appearance), papillary architecture with fibrovascular cores, psammoma bodies, and lymphatic spread pattern with cervical lymph node involvement in 20-50% of cases at presentation.

Pathogenesis involves genetic alterations including BRAF V600E mutation (40-70%), RET/PTC rearrangements (20-40%, especially radiation-induced), RAS mutations (5-15%), TERT promoter mutations (associated with aggressive behavior), and TP53 alterations (in poorly differentiated areas). Risk factors include radiation exposure (especially in childhood), iodine deficiency or excess, family history (familial PTC accounts for 5%), inherited syndromes (Cowden syndrome, familial adenomatous polyposis, Carney complex), and possibly female hormonal factors. Variants include classical PTC (most common), follicular variant, tall cell variant (more aggressive), columnar cell variant (more aggressive), diffuse sclerosing variant (younger patients, often with extensive metastases), and papillary microcarcinoma (≤1 cm, typically indolent).

Diagnosis includes thyroid ultrasound for suspicious nodule features (hypoechogenicity, irregular margins, microcalcifications, taller-than-wide shape), fine-needle aspiration cytology (gold standard, Bethesda categories), molecular testing for indeterminate cytology (Afirma, ThyroSeq), thyroid function tests, and neck staging ultrasound. Management depends on tumor characteristics, lymph node status, and patient factors: thyroid lobectomy for low-risk PTC ≤4 cm without high-risk features, total thyroidectomy with central neck dissection for larger or high-risk tumors, lateral neck dissection for clinically positive lymphadenopathy, radioactive iodine ablation for intermediate and high-risk patients, and TSH suppression therapy with levothyroxine. Active surveillance is increasingly accepted for papillary microcarcinomas. Long-term surveillance includes thyroglobulin measurement, neck ultrasound, and whole-body iodine scans when indicated. Prognosis is excellent with 10-year survival >95% in low-risk disease, but may be lower in advanced or aggressive variants.